Taurine, an amino-sulfonic acid mainly sourced from food, suppresses blood glucose by stimulating insulin secretion from pancreatic β-cells. However, its relationship with glucagon-like peptide-1 (GLP-1) secretion from enteroendocrine L cells is unclear. This study aimed to determine the role of taurine in GLP-1 secretion from L cells. Taurine administration promoted GLP-1 secretion in enteroendocrine L cell line GLUTag cells and increased plasma GLP-1 in mice. Taurine uptake via the taurine transporter increased cytosolic ATP levels, resulting in higher intracellular Ca concentrations and enhanced GLP-1 secretion through ATP-sensitive K channel closure. These findings may help identify new therapeutic targets for obesity and diet-related disease prevention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/1873-3468.70014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glucagon-Like Peptide-1 Receptor Agonists: What's the Optimizing Policies for Obesity-Related Metabolic Diseases?
Diabetes Metab J
March 2025
Division of Endocrinology and Metabolism, Department of Internal Medicine, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea.
Vertical sleeve gastrectomy and semaglutide have distinct effects on skeletal health and heart function in obese male mice.
Am J Physiol Endocrinol Metab
March 2025
MaineHeath Institute for Research, Center for Molecular Medicine, Scarborough, Maine, United States.
Obesity is a global health challenge associated with significant metabolic and cardiovascular risks. Bariatric surgery and GLP-1 receptor agonists (GLP-1RAs) are effective interventions for weight loss and metabolic improvement, yet their comparative effects on systemic metabolism-particularly energy metabolism, bone health, and heart function-remain unclear. In this study, obese male mice underwent vertical sleeve gastrectomy (VSG), 6 weeks of GLP-1RA (semaglutide) treatment, or sham procedure with saline injection as controls.
View Article and Find Full Text PDFInsights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology.
Cells
March 2025
Fondazione CNR-Regione Toscana G Monasterio, Via G. Moruzzi 1, 56124 Pisa, Italy.
In recent years, new drugs for the treatment of type 2 diabetes (T2D) have been proposed, including glucagon-like peptide 1 (GLP-1) agonists or sodium-glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. Over time, some of these agents (in particular, GLP-1 agonists and SGLT2 inhibitors), which were initially developed for their glucose-lowering actions, have demonstrated significant beneficial pleiotropic effects, thus expanding their potential therapeutic applications. This review aims to discuss the mechanisms, pleiotropic effects, and therapeutic potential of GLP-1, DPP-4, and SGLT2, with a particular focus on their cardiorenal benefits beyond glycemic control.
View Article and Find Full Text PDFDanuglipron Ameliorates Pressure Overload-Induced Cardiac Remodelling Through the AMPK Pathway.
J Cell Mol Med
March 2025
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, P.R. China.
Cardiac remodelling, a pathological process induced by various cardiovascular diseases, remains a significant challenge in clinical practice. Here, we investigate the potential of Danuglipron (PF-06882961, PF), a novel oral glucagon-like peptide-1 (GLP-1) receptor agonist, in alleviating pressure overload (PO)-induced cardiac hypertrophy and fibrosis. Using both in vivo and in vitro models, we demonstrate that PF treatment (1 mg/kg/day, orally for 8 weeks) significantly attenuates aortic banding-induced cardiac dysfunction and pathological remodelling in mice.
View Article and Find Full Text PDFGLP-1 as a regulator of sepsis outcomes: Insights into cellular metabolism, inflammation, and therapeutic potential.
Int Immunopharmacol
March 2025
Department of Emergency and Critical Care Medicine, The Second Hospital of Jilin University, NO.218 Ziqiang Street, Changchun, 130041, People's Republic of China. Electronic address:
Glucagon-like peptide-1 (GLP-1) has been widely studied in the context of treating obesity and various forms of metabolic disease. Sepsis is a life-threatening medical emergency characterized by the widespread dysregulation of energy metabolism within cells. The potential for GLP-1 to improve sepsis patient outcomes through improvements in energy metabolism and inflammation has been a focus of growing research interest, with many studies of GLP-1 itself and related compounds, including GLP-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 (DPP-4) inhibitors, having explored the impact on sepsis in cells and organs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!